186Re-maSGS-ZHER2:342, a potential Affibody conjugate for systemic therapy of HER2-expressing tumours

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 2, 2010, Pages 260-269

  Orlova, Anna ^a   Tran, Thuy A ^a   Ekblad, Torun ^b   Karlström, Amelie Eriksson ^b   Tolmachev, Vladimir ^a,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affibody molecules; Chelator; HER2; Mercaptoacetyl; Rhenium

Indexed keywords

CHELATING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCONIC ACID; MERCAPTOACETYLGLYCYL SERYL GLYCYL; RHENIUM 186; TECHNETIUM 99M; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSIMETRY; ISOTOPE LABELING; KIDNEY PARENCHYMA; MOUSE; NONHUMAN; PATIENT SELECTION; PLASMA CLEARANCE; PROTEIN EXPRESSION; RADIOACTIVITY; SYSTEMIC THERAPY; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; ORGAN SPECIFICITY; OVARIAN NEOPLASMS; RADIATION DOSAGE; RADIOISOTOPES; RADIOMETRY; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; RHENIUM; TISSUE DISTRIBUTION;

EID: 77949268342     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1268-9     Document Type: Article

References (44)

1. RM Sharkey DM Goldenberg 2005 Perspectives on cancer therapy with radiolabeled monoclonal antibodies J Nucl Med 46 Suppl 1 115S 127S 1:CAS:528:DC%2BD2MXhsVeksb8%3D 15653660
2. V Kenanova AM Wu 2006 Tailoring antibodies for radionuclide delivery Expert Opin Drug Deliv 3 53 70 10.1517/17425247.3.1.53 1:CAS:528: DC%2BD2MXhtlCms7zI 16370940 (Pubitemid 43056391)
3. DM Goldenberg JF Chatal J Barbet O Boerman RM Sharkey 2007 Cancer imaging and therapy with bispecific antibody pretargeting Update Cancer Ther 2 19 31 10.1016/j.uct.2007.04.003 18311322 (Pubitemid 46970909)
4. M de Jong WA Breeman DJ Kwekkeboom R Valkema EP Krenning 2009 Tumor imaging and therapy using radiolabeled somatostatin analogues Acc Chem Res 42 873 880 10.1021/ar800188e 19445476
5. K Nord E Gunneriusson J Ringdahl S Ståhl M Uhlén PÅ Nygren 1997 Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain Nat Biotechnol 15 772 777 10.1038/nbt0897-772 1:CAS:528:DyaK2sXkvFajsL0%3D 9255793
6. PÅ Nygren 2008 Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold FEBS J 275 2668 2676 10.1111/j.1742-4658.2008.06438.x 1:CAS:528:DC%2BD1cXnt1CjsrY%3D 18435759 (Pubitemid 351678678)
7. A Orlova M Magnusson TL Eriksson M Nilsson B Larsson I Höidén-Guthenberg, et al. 2006 Tumor imaging using a picomolar affinity HER2 binding affibody molecule Cancer Res 66 4339 4348 10.1158/0008-5472.CAN-05-3521 1:CAS:528:DC%2BD28XjsFSltbs%3D 16618759
8. A Orlova V Tolmachev R Pehrson M Lindborg T Tran M Sandström, et al. 2007 Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors Cancer Res 67 2178 2186 10.1158/0008-5472.CAN-06-2887 1:CAS:528:DC%2BD2sXitlSjs78%3D 17332348 (Pubitemid 46424237)
9. T Engfeldt A Orlova T Tran A Bruskin C Widström AE Karlström, et al. 2007 Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence Eur J Nucl Med Mol Imaging 34 722 733 10.1007/s00259-006-0266-4 1:CAS:528:DC%2BD2sXks1agsLY%3D 17146656 (Pubitemid 46669355)
10. T Tran T Engfeldt A Orlova C Widström A Bruskin V Tolmachev, et al. 2007 In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules Bioconjug Chem 18 549 558 10.1021/bc060291m 1:CAS:528:DC%2BD2sXisVGmu7c%3D 17330952 (Pubitemid 46493528)
11. A Orlova J Feldwisch L Abrahmsén V Tolmachev 2007 Update: affibody molecules for molecular imaging and therapy for cancer Cancer Biother Radiopharm 22 573 584 10.1089/cbr.2006.004-U 1:CAS:528:DC%2BD2sXht1GrsLvK 17979560 (Pubitemid 350058993)
12. T Engfeldt B Renberg H Brumer PÅ Nygren AE Karlström 2005 Chemical synthesis of triple-labelled three-helix bundle binding proteins for specific fluorescent detection of unlabelled protein Chembiochem 6 1043 1050 10.1002/cbic.200400388 1:CAS:528:DC%2BD2MXlsVSqtbo%3D 15880677 (Pubitemid 40825345)
13. T Engfeldt T Tran A Orlova C Widström J Feldwisch L Abrahmsen, et al. 2007 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule Eur J Nucl Med Mol Imaging 34 1843 1853 10.1007/s00259-007-0474-6 1:CAS:528:DC%2BD2sXhtFylu7zO 17565496 (Pubitemid 47599054)
14. T Ekblad T Tran A Orlova C Widström J Feldwisch L Abrahmsen, et al. 2008 Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake Eur J Nucl Med Mol Imaging 34 1843 53
15. T Tran T Engfeldt A Orlova C Widström A Bruskin V Tolmachev, et al. 2008 99mTc-maEEE-ZHER2:342, an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors Bioconjug Chem 18 1956 1964 10.1021/bc7002617
16. MA Fortin A Orlova PU Malmström V Tolmachev 2007 Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma Int J Mol Med 19 285 291 1:CAS:528:DC%2BD2sXhvFCksro%3D 17203203
17. A Orlova D Rosik M Sandstrom H Lundqvist L Einarsson V Tolmachev 2007 Evaluation of [111/114mIn]CHX-A''-DTPA-ZHER2:342, an Affibody ligand conjugate for targeting of HER2-expressing malignant tumors Q J Nucl Med Mol Imaging 51 314 323 1:STN:280:DC%2BD2srps1OgtQ%3D%3D 17464277
18. V Tolmachev A Orlova R Pehrsson K Andersson M Sandström D Rosik, et al. 2007 Radionuclide therapy of HER2-positive micro-xenografts using a 177Lu-labeled HER2-specific Affibody molecule Cancer Res 67 2773 2782 10.1158/0008-5472.CAN-06-1630 1:CAS:528:DC%2BD2sXivV2nsLk%3D 17363599 (Pubitemid 46548966)
19. H Wållberg A Orlova 2008 Slow internalisation of anti-HER2 Affibody monomer: implications for development of labeled tracers Cancer Biother Radiopharm 23 435 442 10.1089/cbr.2008.0464 18771347
20. S Ahlgren A Orlova D Rosik M Sandström A Sjöberg B Baastrup, et al. 2008 Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant Affibody molecules Bioconjug Chem 19 235 243 10.1021/bc700307y 1:CAS:528:DC%2BD1cXntV2g 18163536 (Pubitemid 351213855)
21. V Tolmachev H Xu H Wållberg S Ahlgren M Hjertman A Sjöberg, et al. 2008 Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules Bioconjug Chem 19 1579 1587 10.1021/bc800110y 1:CAS:528:DC%2BD1cXosVejtrw%3D 18620447
22. M Persson V Tolmachev K Andersson L Gedda M Sandström J Carlsson 2005 [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells Eur J Nucl Med Mol Imaging 32 1457 1462 10.1007/s00259-005-1902-0 1:CAS:528:DC%2BD2MXht1ygu7%2FJ 16193312 (Pubitemid 41746851)
23. G Liu DJ Hnatowich 2007 Labeling biomolecules with radiorhenium: a review of the bifunctional chelators Anticancer Agents Med Chem 7 367 377 10.2174/187152007780618144 1:CAS:528:DC%2BD2sXksVWhurk%3D 17504162
24. GW Visser M Gerretsen JD Herscheid GB Snow G van Dongen 1993 Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol J Nucl Med 34 1953 63 1:CAS:528:DyaK2cXktVCjurg%3D 8229241
25. S Kinuya K Yokoyama K Kobayashi S Motoishi K Onoma N Watanabe, et al. 2001 Experimental radioimmunotherapy with 186Re-MAG3-A7 anti-colorectal cancer monoclonal antibody: comparison with 131I-counterpart Ann Nucl Med 15 199 202 10.1007/BF02987831 1:CAS:528:DC%2BD3MXmsl2gsLg%3D 11545188
26. MJ Koppe RP Bleichrodt AC Soede AA Verhofstad DM Goldenberg WJ Oyen, et al. 2004 Biodistribution and therapeutic efficacy of 125/131I-, 186Re-, 88/90Y-, or 177Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin J Nucl Med 45 1224 1232 1:CAS:528:DC%2BD2cXnsFygsb0%3D 15235070
27. ME Moustapha GJ Ehrhardt CJ Smith LP Szajek WC Eckelman SS Jurisson 2006 Preparation of cyclotron-produced 186Re and comparison with reactor-produced 186Re and generator-produced 188Re for the labeling of bombesin Nucl Med Biol 33 81 89 10.1016/j.nucmedbio.2005.09.006 1:CAS:528:DC%2BD28XhtFWitr4%3D 16459262 (Pubitemid 43184081)
28. JE Cyr DA Pearson DM Wilson CA Nelson M Guaraldi MT Azure, et al. 2007 Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies J Med Chem 50 1354 1364 10.1021/jm061290i 1:CAS:528:DC%2BD2sXhvFags7k%3D 17315859 (Pubitemid 46496334)
29. P Arora TG Oas JK Myers 2004 Fast and faster: a designed variant of the B-domain of protein A folds in 3 microsec Protein Sci 13 847 853 10.1110/ps.03541304 1:CAS:528:DC%2BD2cXivFakt7s%3D 15044721 (Pubitemid 38429208)
30. CB Liu GZ Liu N Liu YM Zhang J He M Rusckowski, et al. 2003 Radiolabeling morpholinos with 90Y, 111In, 188Re and 99mTc Nucl Med Biol 30 207 214 10.1016/S0969-8051(02)00389-X 1:CAS:528:DC%2BD3sXhs1Cksrs%3D 12623121 (Pubitemid 36293723)
31. T Qu Y Wang Z Zhu M Rusckowski DJ Hnatowich 2001 Different chelators and different peptides together influence the in vitro and mouse in vivo properties of 99mTc Nucl Med Commun 22 203 215 10.1097/00006231-200102000-00013 1:CAS:528:DC%2BD3MXisVeqsbw%3D 11258408 (Pubitemid 32222637)
32. K Lei M Rusckowski F Chang T Qu G Mardirossian DJ Hnatowich 1996 Technetium-99m antibodies labeled with MAG3 and SHNH: an in vitro and animal in vivo comparison Nucl Med Biol 23 917 922 10.1016/S0969-8051(96)00131-X 1:CAS:528:DyaK28XnsFGlur4%3D 8971860 (Pubitemid 26392234)
33. DJ Hnatowich F Chang T Qu M Rusckowski 1999 Technetium-99m labeled peptides - an investigation of multiple HPLC peaks Appl Radiat Isot 50 911 921 10.1016/S0969-8043(98)00157-2 1:CAS:528:DyaK1MXitlalsrc%3D 10214710 (Pubitemid 29138978)
34. M Rusckowski T Qu S Gupta A Ley DJ Hnatowich 2001 A comparison in monkeys of (99m)Tc labeled to a peptide by 4 methods J Nucl Med 42 1870 1877 1:CAS:528:DC%2BD38XktlOktbs%3D 11752087
35. AH Brouwers JE van Eerd C Frielink E Oosterwijk WJ Oyen FH Corstens, et al. 2004 Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re J Nucl Med 45 327 337 1:CAS:528:DC%2BD2cXitVCrtbs%3D 14960657
36. MG Steffens MH Kranenborg OC Boerman NE Zegwaart-Hagemeier FM Debruyne FH Corstens, et al. 1998 Tumor retention of 186Re-MAG3, 111In-DTPA and 125I labeled monoclonal antibody G250 in nude mice with renal cell carcinoma xenografts Cancer Biother Radiopharm 13 133 139 10.1089/cbr.1998.13.133 1:CAS:528:DyaK1cXjsFCisrw%3D 10850349
37. WE Meijs HJ Haisma RP Klok FB van Gog E Kievit HM Pinedo, et al. 1997 Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice J Nucl Med 38 112 118 1:CAS:528:DyaK2sXotlemtg%3D%3D 8998164
38. V Tolmachev FY Nilsson C Widström K Andersson D Rosik L Gedda, et al. 2006 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors J Nucl Med 47 846 853 1:CAS:528:DC%2BD28XltFaiu74%3D 16644755 (Pubitemid 46772889)
39. DM Goldenberg 2002 Targeted therapy of cancer with radiolabeled antibodies J Nucl Med 43 693 713 1:CAS:528:DC%2BD38XktlOlur0%3D 11994535
40. R Valkema SA Pauwels LK Kvols DJ Kwekkeboom F Jamar M de Jong, et al. 2005 Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0, Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate J Nucl Med 46 Suppl 1 83S 91S 1:CAS:528:DC%2BD2MXhsVeksLk%3D 15653656
41. R Nahta FJ Esteva 2007 Trastuzumab: triumphs and tribulations Oncogene 26 3637 3643 10.1038/sj.onc.1210379 1:CAS:528:DC%2BD2sXlslCqsbY%3D 17530017 (Pubitemid 46842713)
42. Y Lu X Zi Y Zhao D Mascarenhas M Pollak 2001 Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin) J Natl Cancer Inst 93 1852 1857 10.1093/jnci/93.24.1852 1:CAS:528:DC%2BD38XltVWluw%3D%3D 11752009
43. LM Bender R Nahta 2008 Her2 cross talk and therapeutic resistance in breast cancer Front Biosci 13 3906 3912 10.2741/2978 1:CAS:528: DC%2BD1cXnsVKqtbY%3D 18508484 (Pubitemid 351594668)
44. M Friedman A Orlova E Johansson T Eriksson I Höidén- Guthenberg V Tolmachev, et al. 2008 Directed evolution to low nanomolar affinity of an epidermal growth factor receptor 1-binding Affibody molecule J Mol Biol 376 1388 1402 10.1016/j.jmb.2007.12.060 1:CAS:528:DC%2BD1cXitVejurY%3D 18207161